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Suboptimal axonal regeneration contributes to
the consequences of nervous system trauma and
neurodegenerative disease, but the intrinsic mech-
anisms that regulate axon growth remain unclear.
We screened 50,400 small molecules for their
ability to promote axon outgrowth on inhibitory
substrata. The most potent hits were the statins,
which stimulated growth of all mouse- and hu-
man-patient-derived neurons tested, both in vitro
and in vivo, as did combined inhibition of the
protein prenylation enzymes farnesyltransferase
(PFT) and geranylgeranyl transferase I (PGGT-1).
Compensatory sprouting of motor axons may
delay clinical onset of amyotrophic lateral sclerosis
(ALS). Accordingly, elevated levels of PGGT1B,
which would be predicted to reduce sprouting,
were found in motor neurons of early- versus
late-onset ALS patients postmortem. The me-
valonate-prenylation pathway therefore consti-
tutes an endogenous brake on axonal growth,
and its inhibition provides a potential therapeutic
approach to accelerate neuronal regeneration in
humans.This is an open access article under the CC BY-NINTRODUCTION
Axonal growth is an essential step in the formation of neural
circuits during normal development. In cases of traumatic brain
injury or neurodegenerative disease, axonal damage is among
the first morphological manifestations, and suboptimal regen-
eration is thought to be a major contributor to the low rates
of functional recovery. Enhancing axonal regeneration in a
controlled manner in patients with spinal cord injury may allow
them to regain key lost functions; similar treatment in patients
with amyotrophic lateral sclerosis (ALS) has the potential to
increase muscle strength over the course of the disease. Over
the past few decades, we have gained considerable insight
into the extrinsic factors and intrinsic signaling mechanisms
that affect directional choices taken by the axon growth cone
and govern its reduced ability to advance in the damaged
CNS (Alizadeh et al., 2015). However, we still have little knowl-
edge of the cell-intrinsic mechanisms that drive axonal forward
growth.
Over the past few decades, much insight has been gained
into the low regenerative capacity of the adult CNS (Liu et al.,
2011; Yiu and He, 2006). Most studies have focused on extrinsic
factors that restrict axon regeneration (Filbin, 2003; Thiede-Stan
and Schwab, 2015). Three growth inhibitors—myelin-associ-
ated glycoprotein (MAG), Nogo, and oligodendrocyte myelin
glycoprotein—act through a common receptor complex con-
taining the ligand-binding Nogo-66 receptor (NgR) and itsCell Reports 16, 545–558, July 12, 2016 ª 2016 545
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A B C
D E
F G
Figure 1. High-Throughput Screen for Small Molecules that Enhance Neurite Outgrowth on Inhibitory Substrata Identifies Statins as the
Most Potent Hits
(A) Fields of live mouse ES-MNs expressing the Hb9::GFP transgene imaged through monolayers of control CHO (Ctrl-CHO) or MAG-CHO cells. False colors are
assigned to individual neurons by MetaMorph, which calculates neurite outgrowth parameters on a cell-by-cell basis. Neurite outgrowth on MAG-CHO cells is
severely restricted, but cell survival is little affected. Scale bar, 100 mm.
(B) ES-MNs and E12.5 primary mouse motor neurons show comparable growth inhibition on MAG-CHO (mean ± SEM, n = 8; p < 0.005 for both ES-MNs and
primary MNs).
(C) Schematic of the high-throughput screen.
(D) A snapshot of a fraction of the screening data. Neurite outgrowth data were converted to fold-increase by normalizing them to the negative controls in each
plate. Data collected from forty 96-well plates are plotted for negative and positive controls, as well as test compounds.
(E) Compound libraries used for the screen. The number of compounds screened, primary hit rate, number of hits validated and number of confirmed lead
compounds (>1.8-fold increase) are indicated.
(legend continued on next page)
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signaling co-receptors p75NTR and paired immunoglobulin-like
receptor B (PirB). Key components of the glial scar are the
chondroitin sulfate proteoglycans (CSPGs), a family of extracel-
lular matrix proteins that inhibit axon outgrowth (Dickendesher
et al., 2012; Lang et al., 2014; Shen et al., 2009; Snow et al.,
2003).
Preventing extrinsic inhibitory signals has real potential for
promoting CNS axon regeneration (Case and Tessier-Lavigne,
2005). In addition, however, complementary approaches aim-
ing to boost axonal growth without targeting a specific inhibi-
tory mechanism also have potential therapeutic impact. Among
small molecules reported to be active on axon growth are
monastrol, an inhibitor of kinesin-5 (Baas and Matamoros,
2015), and inhibitors of the mevalonate pathway, through which
cholesterol and isoprenoids are synthesized from acetyl-coen-
zyme A (Figure 3A; Pooler et al., 2006). However, the latter
compounds were tested at high concentrations that have
been found to be cytotoxic in other studies (Butterfield et al.,
2011). Moreover, those small molecules that have been shown
to be effective in the CNS in vivo, such as cyclic AMP (cAMP)/
rolipram, ROCK inhibitor, and polyamines, lack the specificity
and potency expected of clinical candidates (Fournier et al.,
2003; Nikulina et al., 2004; Cai et al., 1999, 2002). There is
therefore a need to explore more broadly ways in which the
suboptimal intrinsic growth capacity of adult CNS neurons
can be boosted.
Phenotypic cell-based screening provides a powerful, unbi-
ased chemical genetic approach to identifying novel mecha-
nisms underlying a given cellular process. Earlier studies
taking this approach to axonal growth used relatively small
screening libraries (<2,000 small molecules; Al-Ali et al.,
2015; Koprivica et al., 2005; Ma et al., 2010; Usher et al.,
2010). We instead developed a high-throughput screen using
neurons grown in the presence of myelin inhibitors. The screen
identified four active compound classes, of which we focused
on the cholesterol-lowering drugs statins. We show that sta-
tins are the most potent agents reported to promote growth
of mouse and human neurons in culture and show strong
regenerative effects when administered to injured CNS neu-
rons in vivo. Statin activity in this system entirely reflects
downstream inhibition of protein prenylation, and specific in-
hibitors of this post-translational modification replicate all the
key effects of statins without perturbing cholesterol meta-
bolism. Strikingly, postmortem motor neurons from patients
with early-onset ALS express abnormally high endogenous
levels of mRNA for the prenylation enzyme geranylgeranyl
transferase I, which our data would predict to reduce their
capacity for compensatory sprouting at the neuromuscular
junction. Taken together, our data identify prenylation as a
common intrinsic regulator of axonal growth rate and point
to novel therapeutic approaches for CNS injury and neurode-
generative disease.(F) Dose-response curves for all nine statins on ES-MNs grown onMAG-CHOmon
MAG after 20 hr in culture. Values are means of six replicates; error bars are not
(G) Cerivastatin is nearly 400-fold more potent than the ROCK inhibitor Y-27632
periments).RESULTS
High-Throughput Screening for Small Molecules that
Promote Neurite Regeneration
To identify mechanisms of axonal regeneration, we developed a
high-throughput neuron-based assay (Figure 1). We used rodent
motor neurons, since drugs screened on primary rat motor
neurons subsequently showed efficacy in the clinic (Bordet
et al., 2007). For ease of scale-up, mouse embryonic stem cell-
derived motor neurons (mES-MNs) expressing an Hb9::GFP
reporter (50% abundance) were employed (ESCs; Wichterle
et al., 2002). To quantify neurite outgrowthwithminimal sampling
error, we used fluorescence live imaging of whole wells in 96-well
format (typically 300–700 neurons imaged per well) followed by
automated image analysis that identified individual neurons
and calculated the neurite length for each (Figure 1A).
To mimic the inhibitory cellular environment of the adult CNS,
ES-MNs were grown on monolayers of CHO cells expressing
MAG (Mukhopadhyay et al., 1994). After 20 hr in culture, neurite
outgrowth of ES-MNs on MAG-CHO cells was only 47% ± 2%
(mean ± SEM, n = 8) of that on control CHO cells (Figures 1A
and 1B), whereas neuronal survival was only slightly affected
(MAG-CHO 92% ± 1% of control; p < 0.008). Primary embryonic
day 12.5 (E12.5) mousemotor neurons showed the same degree
of growth inhibition on MAG-CHO cells (Figure 1B). Increasing
cAMP levels has been shown to overcome MAG inhibition of
axonal growth (Qiu et al., 2002), and the phosphodiesterase in-
hibitor rolipram promotes regeneration in vivo (Nikulina et al.,
2004). Accordingly, forskolin promoted neurite growth in our
assay, with a half-maximal effective concentration (EC50) of
0.85 ± 0.08 mM (Figure S1A), as did a combination of forskolin
(10 mM) and IBMX (100 mM), which was used as a positive control
for the screen (Figure S1B). Our assay therefore faithfully repro-
duced the activity of compounds known to enhance axonal
regeneration in vivo.
We screened a library of 50,401 compounds at a single con-
centration (10 mM) for their ability to overcome MAG inhibition
(Figure 1C; see Experimental Procedures for the compound
collections tested and for assay optimization procedures).
Approximately 98% of compounds showed no significant effect
on neurite outgrowth, while a minority were toxic (Figures 1D and
1E). Initial hits were defined as compounds that increased
neurite outgrowth by >30% (initial hit rate, 1.6%; Figure 1E). In
repeat assays using five-point 2-fold dilution series, 151
compounds were confirmed to be active. Of these, 91 were
reordered from vendors and tested in a nine-point 2-fold dilution
series in six replicates. Finally, four compounds that enhanced
neurite outgrowth by >80% at their optimal concentration(s)
were selected as leads (Figure S1C). One was a hitherto
undescribed compound with no identified target. The second
lead shows 90% similarity to a class of phosphodiesterase 4
inhibitors (PDE4; Skoumbourdis et al., 2008) and likely acts byolayers. Note that six out of nine statins enhance neurite outgrowth >2-fold over
shown for clarity.
(mean ± SEM; n = 6 wells; data are representative of three independent ex-
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Figure 2. Statins Enhance Neurite Growth of
Multiple Neuronal Classes on All Culture
Substrata Tested
Effects of statins on neurite outgrowth were
measured using different neuronal preparations
cultured on both inhibitory and permissive sub-
strata.
(A) Purifiedmouse ES-MNs, enrichedmouse spinal
motor neurons from E12.5 embryos (primary MNs),
primary cerebellar granule neurons from post-
natal day 2 (P2) to P6 mice (CGN), and primary
hippocampal neurons from P1 rats (HN) grown on
MAG-CHO monolayers all respond to cerivastatin
in the sub-micromolar range.
(B) Primary (E12.5) motor neurons were grown
on MAG-CHO monolayers in the presence of
the indicated concentrations of cerivastatin and
simvastatin. As with ES-MNs, the maximal ef-
fects are similar but cerivastatin is 10-fold more
potent.
(C) Growth of mouse ES-MNs is enhanced
by cerivastatin on another inhibitory substratum
(CSPG) and even in the most permissive culture
conditions (polyornithine-laminin).
(D) Cerivastatin enhances growth on both CHO
andMAG-CHO layers with a similar maximum level
of outgrowth (C and D: mean ± SEM; n = 6; data
are representative of at least three independent
experiments).increasing endogenous cAMP levels. The third lead (Figure S1C)
bore a close resemblance to a family of kinesin-5 inhibitors,
others of which have been reported to trigger axonal outgrowth
in culture (Haque et al., 2004). Our open-ended screen was
therefore able to detect modulators of known growth-inhibitory
pathways. However, we detected no biological activity in this
system for either of two small molecules reported to show neu-
rite outgrowth-promoting properties: daidzein (Ma et al., 2010)
or erlotinib (Koprivica et al., 2005; Figure S1D). Subsequently,
therefore, we focused on the fourth and most potent lead,
simvastatin.
Statins Act Directly on CNS Neurons to Promote Neurite
Outgrowth on Multiple Substrata
Simvastatin is a widely used cholesterol-lowering drug. Six of
the other commercially available drugs (cerivastatin, fluvastatin,
simvastatin, lovastatin, mevastatin, and pitavastatin) enhanced
ES-MN neurite outgrowth on MAG by >2-fold at concentrations
ranging from 30 nM to 7 mM (Figure 1F). The remaining three
(pravastatin, rosuvastatin, and atorvastatin) showed only weak
activity, perhaps because they were designed to be selective
for liver cells (Buckett et al., 2000; McTaggart et al., 2001). Cer-
ivastatin was the most potent and induced a 3-fold increase
in neurite outgrowth with an EC50 of 33.6 ± 2.2 nM (mean ±
SEM; n = 6), completely overcoming MAG inhibition (Figure 3B).
Cerivastatin was 380-fold more potent in this system than
the benchmark ROCK inhibitor Y-27632 (Figure 1G) (Fournier
et al., 2003). We therefore used cerivastatin as a tool com-548 Cell Reports 16, 545–558, July 12, 2016pound to study the mechanism of action of statins on neurite
outgrowth.
To exclude the possibility that statins act indirectly through
other cell types in the culture, we showed that MAG protein
levels in MAG-CHO cells were not changed (Figures S2A and
S2B) and that the effects of cerivastatin on fluorescence-acti-
vated cell sorting (FACS)-purified ES-MNs were similar to those
on mixed cultures, increasing outgrowth 2.5-fold with an EC50
of 94.7 ± 6.9 nM (Figure 2A). Primary motor neurons from
E12.5 ventral spinal cord from Hb9::GFP mice responded
similarly to statins, though at slightly higher doses than for
ES-MNs (Figures 2A and 2B). Lastly, both primary hippocampal
(HN) and primary cerebellar granule neurons (CGN) respond to
statins (Figure 2A). Thus, statins act directly on all neuronal
populations tested.
To determine whether statins only inhibit a MAG-specific
signaling mechanism (Filbin, 2003) or act more broadly on
regeneration, we administered cerivastatin to ES-MNs grown
on different substrata. Cerivastatin was also effective when
CSPG was added to the culture medium (Figure 2C). Even on
two permissive substrata, polyornithine-laminin and control
CHO cells (which showed higher basal neurite outgrowth), we
observed a significant increase in outgrowth (Figures 2C and
2D). Although cerivastatin has a significant effect on neurite initi-
ation, its strongest dose-dependent effects are on axon elonga-
tion (Figures S2C–S2F). Therefore, statins act as potent general
promoters of neurite outgrowth on all substrata tested, sug-
gesting that basal levels of signaling through the mevalonate
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Figure 3. Statins Promote Neurite Growth
by Inhibiting Both Prenylation Pathways
(A) Key intermediates in the mevalonate pathway
leading to cholesterol and other isoprenoid
biosynthesis as well as protein prenylation.
(B) A fixed concentration (500 nM) of cerivastatin
completely overcomes MAG inhibition of ES-MN
growth, but its effects are progressively canceled
out by increasing concentrations of mevalonate
(MVL). There is no effect of MVL on axonal growth
in the absence of statins (mean ± SEM; n = 6).
(C and D) Farnesyl pyrophosphate (Fpp) (C) and
geranylgeranyl pyrophosphate (GGpp) (D) can also
reverse the growth-promoting effect of statins
without affecting intrinsic growth rates on either Ctrl-
CHOorMAG-CHOmonolayers (mean±SEM;n=6).
(E) Mixed inhibitors of geranylgeranyl transferase
(GGTI) and farnesyl transferase (FTI) enhance
neurite outgrowth on MAG-CHO.
(F) More selective inhibitors (GGTI-2417 and FTI-
2153) promote neurite outgrowth synergistically,
since the value for increased length above base-
line is more than additive (mean ± SEM; n = 6, p <
0.001). Note that a combination of both inhibitors
drives neurite outgrowth to levels comparable to
those of vehicle-treated neurons on non-inhibitory
control CHO cells (unfilled bar).pathway provide a brake on axonal growth even on the most
supportive substrata.
Statins Promote Neurite Outgrowth by Inhibiting
3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase
The cognate target of all statins is the enzyme 3-hydroxy-3-meth-
ylglutaryl-coenzyme A (HMG-CoA) reductase (HMGCR), which
catalyzes a rate-limiting upstreamstep in cholesterol biosynthesis
(Figure 3A). If statins stimulate axonal growth by inhibiting
HMGCR, adding back the enzyme product mevalonate (which is
cell permeable) in the presence of statin should restore inhibition.
Mevalonatealonehad noeffect onneurite growthoneither control
orMAG-CHOmonolayers,while addition of increasing concentra-
tions of mevalonate in the presence of a fixed 500 nM concentra-
tion of statin, itself capable of completely overcomingmyelin inhi-
bition, fully reconstituted inhibition byMAG (Figure 3B). Therefore,
HMGCR inhibition accounts for all neurite-promoting actions of
cerivastatin, and endogenous levels ofmevalonate are not limiting
for full inhibition by MAG. Nevertheless, inhibiting this pathway
necessarily leads to reductions in the levels of cholesterol, whichCcould be damaging in the CNS, where it
plays multiple roles in synapse function.
We therefore sought a means to mimic
the biological effects of statins on axon
growth without affecting cholesterol.
Inhibition of Protein Prenylation
Accounts for the Statin-Induced
Increase in Axonal Growth
DownstreamofHMGCR,multiplebranches
of themevalonate pathway lead to the syn-
thesis of isoprenoids involved in the syn-thesis of cholesterol as well as lipid intermediates required for
post-translational protein prenylation (Figure 3A; van der Most
et al., 2009; Corsini et al., 1999). We examined the role of
each in the inhibition of neurite outgrowth. The last interme-
diate common to all the branches is farnesyl pyrophosphate
(Fpp). Using add-back experiments (Wasko et al., 2011), we
confirmed that Fpp prevents growth enhancement by cerivas-
tatin (Figure 3C). In contrast, neither coenzyme Q4 or Q10
(from the left-hand branch in Figure 3A) nor high-density lipo-
protein (HDL)- or low-density lipoprotein (LDL), which affect
cholesterol synthesis, reconstituted the growth inhibition (Fig-
ures S3B–S3E), demonstrating that it is not necessary to block
cholesterol or coenzyme Q synthesis to enhance neurite
outgrowth.
However, application of GGpp to ES-MN cultures treated with
cerivastatin completely restored inhibition by MAG (Figures 3C
and 3D). The strong, selective effects of Fpp and GGpp pointed
to inhibition of protein prenylation as the principal mode of statin
action in our system. To confirm the involvement of prenylation
enzymes, we first tested small-molecule inhibitors GGTI-298ell Reports 16, 545–558, July 12, 2016 549
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and FTI-277, each of which is incompletely selective (see Fig-
ure S3A for in vitro half-maximal inhibitory concentration (IC50)
values for both PGGT-1 and PFT). Both promoted neurite growth
in a dose-dependent manner (GGTI-298: EC50 = 2.6 ± 0.21 mM,
n = 7; FTI-277: 5.6 ± 0.21 mM, n = 6; Figure 3E). To determine
whether one or both of the two prenylation pathways was
involved, inhibitors with greater specificity for their respective
targets, GGTI-2417 and FTI-2153, were tested (Figure S3A).
Tested alone, GGTI-2417 had no significant effect (p = 0.266)
whereas FTI-2153 led to a 1.7-fold increase in neurite outgrowth
(p < 0.001; Figure 3F). Strikingly, though, their actions were
strongly synergistic (p < 0.001 for a synergistic as opposed
to additive effect; Bliss model). The combined inhibition of
PGGT-1 and PFT was sufficient to induce a 3-fold increase in
axon outgrowth onMAGover the 20-hr culture period (Figure 3F).
The resulting growth on MAG was similar to that on control CHO
cells. Therefore, inhibition of dual protein prenylation pathways
can stimulate axonal growth without inhibiting cholesterol syn-
thesis (Figure 6F).
Statins and Prenylation Inhibitors Promote CNS Axon
Regeneration In Vivo
To explore the role of this mechanism in mature CNS neurons
in vivo, we used the optic nerve crush model, in which com-
pounds applied into the eye gain direct access to injured retinal
ganglion cells (RGCs) (Figure 4). The optic nerve of 6- to 8-week-
old mice was injured by pinching with forceps, and immediately
afterward, a total volume of 2 ml saline, 25 mM cerivastatin, 50 or
100 mM GGTI-2417 (GGTI), 50 or 100 mM FTI-2153 (FTI), or a
combination of 50 mM GGTI and 50 mM FTI was intravitreally in-
jected into the peripheral zone of the eye. The final total (free +
bound) concentrations of these compounds in the vitreous was
estimated to be in the micromolar range. At 14 days post-injury,
live regenerating axons were labeled by anterograde tracing
using labeled cholera toxin b-subunit and fixed 3 days later (Fig-
ure 4A).We confirmed that the same axons expressedGAP-43, a
marker of regenerating axons (Figure S4; Koprivica et al., 2005).
Mice treated with saline showed few regenerating axons distal to
the lesion site (Figure 4A). However, following treatment with cer-
ivastatin, robust regrowth of RGC axons was observed (average
of five longest axons: saline = 371 ± 64 mm versus cerivastatin =
1,618 ± 137 mm, p < 0.01; Figures 4A and 4C). To provide a more
complete measure, we quantified cholera toxin B subunit (CTB)
labeling on serial sections of optic nerves at different distances
from the lesion (Figure 4B). There was a highly significant effect
(p < 0.01) of cerivastatin as compared to saline control at allFigure 4. Both Cerivastatin and a Combination of Prenylation Inhibitor
(A) Enhancement of retinal axon regeneration by cerivastatin and protein prenylati
the time of lesion GGTI-2417 (GGTI). 10-mm cryosections through optic nerve 14 d
the injury site in cerivastatin or (GGTI + FTI)-treated mice as compared to saline.
(B and C) Quantitative analysis of regrowing axons in saline, cerivastatin, or p
regenerating axons in 200-mm columns progressively further from the lesion site o
the lesion site of the five longest axons was analyzed in (C). Note that cerivasta
regrowth by either measure. All data from quantification of axon regeneration are e
50 mM GGTI, n = 4 for 50 mM FTI, n = 3 for 100 mM GGTI, n = 3 for 100 mM FTI, a
(D and E) No effect on RGC survival of either cerivastatin or protein prenylation inhi
RGCs (D), and quantitative analysis of the number of Tuj1+ RGCs in saline, ceriva
nerve injury in (E). All data in (E) are expressed as mean ± SEM; n = 3 for each cpositions in the nerve. Following nerve crush in 24-week-old
mice, statin treatment also conferred benefit (not shown).
We next askedwhether, as in vitro, prenylation inhibitors could
mimic the beneficial effect of statins. Effects of the combination
of 50 mMGGTI-2417 and 50 mM FTI-2153 were indistinguishable
from that of cerivastatin, at all distances from the lesion (Figures
4A–4C). Strikingly, neither of the inhibitors used singly had a
robust effect on optic nerve regeneration, making the synergistic
effect of the combination highly significant (p < 0.01; Figure 4C).
One possible explanation of the increased axonal growth might
have been protection of RGCs from injury-induced death, which
we determined to be 77% after 2 weeks in saline-treated mice
(Figures 4D and 4E). However, no neuroprotective effect of either
cerivastatin or a combination of GGTI + FTI was observed (Fig-
ures 4D and 4E), suggesting that both agents act primarily to
enhance growth of regenerating CNS axons in vivo.
Significance of theMevalonate andPrenylation Pathway
for Axonal Degeneration and Regeneration in Human
Patients with ALS
All experiments thus far had used mouse models. We therefore
tested inhibitors on two systems of human stem cell-derived
motor neurons: the ‘‘gold-standard’’ ES-derived motor neurons
expressing an Hb9::GFP reporter as well as human induced
pluripotent stem cell-derived motor neuron (hiPS-MNs) derived
from ALS patients and controls (Amoroso et al., 2013, Boulting
et al., 2011, Maury et al., 2015). Human neurons grew well on
control CHO cells and, like their mouse counterparts, showed
clear growth inhibition on aMAG-CHO cell monolayer (Figure 5A)
but little reduction in survival (values for MAG-CHO were 89%–
92% of those on control CHO cells). Addition of cerivastatin
led to a dose-dependent, 6-fold increase in axon length over
the 20-hr culture period (Figures 5A and 5B). The fold-increase
of neurite length was even stronger than on mouse motor neu-
rons, though the EC50 was higher (390 ± 56 nM; n = 6). Hb9::GFP
motor neurons in mixed cultures (30% abundance) or purified
by FACS responded in a comparablemanner to cerivastatin (Fig-
ure 5B). Introduction of an ALS-causing point mutation into the
SOD1 gene of the same ES line only modestly reduced the
ES-MN response to statins (Figure 5C). To directly confirm that
statins can affect human ALS motor neurons, we generated
hiPS-MNs from the 007 human induced pluripotent stem cell
(hiPSC) line derived from a patient with an SOD1A4V point muta-
tion, as well as an isogenic control line in which the mutation had
been corrected (Figure 5D). Cerivastatin strongly promoted neu-
rite outgrowth from both, and once again, ALS motor neuronss Strongly Promote Retinal Axon Regeneration In Vivo
on inhibitors, GGTI-2417 (GGTI) and FTI-2153 (FTI) administered intravitreally at
ays later show increased numbers of CTB-labeled regenerating axons distal to
rotein prenylation inhibitor-treated mice. Mean gray values of CTB-labeled
btained at constant illumination are shown in a.u. in (B), and the distance from
tin or combinations of GGTI and FTI led to 4-fold increases in retinal axon
xpressed asmean ± SEM; n = 4 for saline, n = 5 for 25 mMcerivastatin, n = 4 for
nd n = 6 for 50 mM GGTI + 50 mM FTI. *p < 0.01.
bitors after optic nerve injury. 10-mmcryosections through the retina show Tuj1+
statin, or prenylation inhibitors (GGTI + FTI)-treated mice with or without optic
ondition. Scale bars represent 100 mm in (A) and 20 mm in (D).
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Figure 5. Human-Patient-Derived Motor
Neurons Show Strong Axonal Growth
Responses to Statins and Prenylation
Inhibitors
(A) Images of human ES-MNs expressing
Hb9::GFP grown on control-CHO and MAG-CHO
with and without cerivastatin. Scale bars, 100 mm.
(B) Mixed and purified human ES-MNs similarly
overcome MAG-induced neurite inhibition in the
presence of cerivastatin with a 6-fold increase in
neurite length in the first 20 hr of culture.
(C and D) Cerivastatin also has marked axonal
growth effects on (C) human ES-MNs with or
without an SOD1A4V mutation knocked in using
zinc-finger technology and (D) hiPS-MNs from a
healthy control or SOD1A4V ALS patient.
(E) Combinations of GGTI-2417 and FTI-2153
overcome inhibition of neurite outgrowth of hiPS-
MNs by MAG-CHO, whereas GGTI or FTI alone
show no effect. Values are plotted as mean ±
SEM; n = 6 replicates. Data are representative of
at least three independent preparations of ES/
hiPS-MNs.responded similarly to their control counterparts. Effects on sur-
vival were minor (<50% increase in the presence of statins as
compared to >600% for neurite outgrowth).
Lastly, we tested the prenylation inhibitors GGTI-2417 and
FTI-2153, alone and in combination, on hiPS-MNs from the
18c healthy control line (Lamas et al., 2014) grown on MAG-
CHO cells (Figure 5E). Their synergistic effects were striking;
neither compound tested alone significantly stimulated axon
growth, but in combination, they triggered a 3-fold increase
over the first 20 hr of culture.
To determine whether protein prenylation might also regulate
growth in adult humanmotor neurons in vivo, we turned to a pub-
lished microarray analysis of lumbar motor neurons that were
laser captured from ALS patients who had died of the bulbar
form of the disease, meaning that many motor neurons still
survived at the less-affected lumbar levels (Rabin et al., 2010).
We interrogated the normalized raw expression data for all en-
zymes in the mevalonate and prenylation pathways, asking
whether there might be differences between ALS and controls,
or between early- and late-onset cases in the cohort of 12 ALS
patients studied. Levels ofmost enzymes in the pathway showed
no significant correlation with age, or difference between early-
versus late-onset ALS (cutoff defined as 60 years; Figure 6A).
The same was true of many other pathways tested (not shown),
suggesting that there was no significant age-dependent meth-
odology bias within the dataset. HMGCR, PFT, and PGGT-2
did not show any variation with age or disease state (Figures
6B–6D). However, one prenylation enzyme showed a striking
correlation. In control motor neurons, PGGT1B, the gene that
encodes PGGT-1, b subunit showed no significant variation
with age. In contrast, in motor neurons from ALS patients, its
levels were higher (6-fold) than controls in early-onset cases
and diminished linearly with age (R2 = 0.62) to reach control
levels in older patients. Despite the small numbers of patients552 Cell Reports 16, 545–558, July 12, 2016analyzed, these differences were highly significant (p = 0.01
for early versus late onset; p = 0.002 for correlation with age).
Importantly, this observation was motor-neuron specific, since
PGGT1B expression in the dorsal spinal cord of the same ALS
patients showed no correlation with age or disease state (data
not shown; Rabin et al., 2010). The only other two mevalonate
pathway genes to show a degree of correlation with age were
ACAT1 and MVD (Figure 6A). However, the difference in expres-
sion levels between early- and late-onset ALSwas low (<1.5-fold
for both genes), suggesting that the functional impact was not
significant.
DISCUSSION
Our understanding of the cell-intrinsic mechanisms that regulate
neurite growth remains incomplete. In particular, there is a crit-
ical need for a means by which to enhance axonal regeneration
in human patients. By conducting an extensive screen for small
molecules able to overcome myelin inhibition, we found that
statins are the most potent neurite growth-promoting agents
yet reported, both for rodent and human neurons. Moreover,
comparable effects on axonal regeneration can be generated,
without blocking cholesterol synthesis, by inhibiting both
branches of the protein prenylation pathway, either in vitro or
in vivo. In all neurons examined, we found that endogenous
levels of prenylation are maintained at a level that constitutes a
brake on axonal growth, and expression data suggest this may
contribute to lack of compensatory sprouting in early-onset
ALS patients. Targeting the mevalonate-prenylation pathway
may therefore allow both preventive and reparative approaches
in human patients with CNS trauma or neurodegenerative
disease.
Other screens reported to date have used different cellular
models and 20-fold-smaller screening libraries (Al-Ali et al.,
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early vs late
ACAT1 Acetoacetyl-CoA  transferase ACAT1 0.008 0.05
ACAT2 Acetoacetyl-CoA  transferase ACAT2 0.653 0.56
HMGCS1 HMG-CoA synthase1 0.884 0.91
HMGCS2 HMG-CoA synthase2 0.372 0.23
HMGCR HMG-CoA reductase 0.915 0.83
MVK Mevalonate kinase 0.220 0.42
PMVK Phosphomevalonate kinase 0.344 0.29
MVD Mevalonate-5-pyrophophate decarboxylase 0.030 0.05
IDI1 Isopentenyl-diphosphate isomerase 1 0.751 0.80
FDPS Farnesyl diphosphate synthase 0.906 0.86
FNTA Farnesyl transferase alpha subunit 0.213 0.12
FNTB Farnesyl transferase beta subunit 0.985 0.96
GGPS1 Geranylgeranyl diphosphate synthase 0.139 0.19
PGGT1B Geranylgeranyl transferase beta subunit 0.002 0.01
RABGGTA Rab geranylgeranyl transferase, alpha subunit 0.534 0.36
RABGGTB Rab geranylgeranyltransferase, beta subunit 0.093 0.31
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2015; Ma et al., 2010; Usher et al., 2010; Koprivica et al., 2005).
Likely reflecting these differences, in our system, we could not
detect activity of either daidzein, which has already been re-
ported to work only when neurons are primed by pre-exposure
to drug (Ma et al., 2010), or erlotinib (Koprivica et al., 2005;
Figure S1D). In our hands, despite the specific nature of our
screening model, statins were effective on all neurons (both
stem cell derived and primary) and all substrata (both inhibitory
and permissive) tested. They seem therefore to trigger a general
boost in axon growth potential.
The tissue that expresses the highest levels of HMGCR is the
brain (Burkhardt et al., 2008). Multiple and often contradictory ef-
fects of statins and prenylation inhibitors on cultured neurons
have been reported. These include changes in directional growth
of axons without any increase in axonal length (Holmberg et al.,
2006), protection of axons against excitotoxicity (Posada-Duque
et al., 2013), decreased neurite length (Schulz et al., 2004, Kim
et al., 2009), or no effect (Fan et al., 2002). The data most com-
parable to ours are those of Pooler et al. (2006), who report a
40% increase in neurite length of hippocampal neurons following
exposure to high concentrations (R100 mM) of pravastatin or
50 mM GGTI-286, but not FTI-277. But these concentrations,
which are at least an order of magnitude above the EC50, were
found to be toxic in our study and other studies (Figures 2C,
2D, and 3E; Butterfield et al., 2011). It is unclear whether these
disparities are due to specificities of neurons and substrata or
the methodology of quantification and cell culture, and in vivo
validation is therefore critical. Our finding that a single intravitreal
injection of statin or prenylation inhibitors was sufficient to sup-
port RGC axonal growth over 2 weeks at levels comparable
with many genetic manipulations was highly encouraging. It is
reasonable to suppose that the effect will be still greater when
the drug can be delivered continuously and in the presence of
an agent that prevents the >75% loss of RGCs caused by axot-
omy and not rescued by cerivastatin.
Inhibition of protein prenylation is considered to play a key
role in many biological effects of statins not directly linked to
cholesterol (Samuel and Hynds, 2010). Hundreds of intracellular
signaling proteins (e.g., small GTP/GDP-binding proteins) may
potentially be prenylated, but only a minority of modifications
have been specifically identified (Samuel and Hynds, 2010;
Charron et al., 2013). Some, like K-Ras, Ras, and H-Ras, areFigure 6. Levels ofPGGT1BAre Selectively Elevated inMotor Neurons o
or Healthy Controls
(A) Based on the raw data of Rabin et al. (2010), for each enzyme in the different bra
difference between ALS and control patients (p value correlation) and the differenc
patients (p value early versus late). Only PGGT1B, which encodes the b subuni
significant fold-difference in expression levels between early- and late-onset cas
(B–E) Scatterplots of expression levels of individual genes analyzed in this study in
indistinguishable for the first three genes (with some scatter for HMGCR), early-o
(R2 = 0.62) with increasing age. No similar change was seen in healthy controls ov
(not shown).
(F) Model showing how prenylation enzymes provide a double brake on axonal g
in vitro and in vivo. Reducing activity or expression level (normal green font) of a sin
both, using either statins or combinations of prenylation inhibitors, leads to a >3-f
motor neurons from early-onset ALS cases have high levels of PGGT-1 but low lev
low levels of both enzymes inmotor neurons from late-onset ALS cases are consis
ability to sprout and reinnervate denervated muscle fibers.
554 Cell Reports 16, 545–558, July 12, 2016exclusively farnesylated, while others, such as Rac, Rho, and
Rap, are geranylgeranylated; lastly, one (RhoB) is modified by
both enzymes (Zhang and Casey, 1996). We found both in vitro
and in vivo that inhibiting both farnesylation and geranylgerany-
lation provided the strongest benefit for axonal growth. This may
suggest a central role for a doubly modified protein, or it may
mean that multiple prenylation substrates are involved. Distin-
guishing between such possibilities is complicated. First,
compensatory prenylation has also been described; when PFT
is inhibited by FTIs, K-Ras and N-Ras, but not H-Ras, become
geranylgeranylated. Second, knockdown or inhibition of Rac1
was shown to mimic the neuroprotective actions of statins on
cortical neurons (Posada-Duque et al., 2013), yet a non-prenylat-
able mutant of Rac1 was recently shown to retain its function in a
neurite outgrowth assay (Reddy et al., 2015).
Given the widespread usage of statins, many authors have
addressed the question of whether they are protective and/or
beneficial in CNS indications. Citing only the most recent
meta-analyses for multiple sclerosis, cognition in Alzheimer’s
disease, and Parkinson’s disease, the response is unclear
(Pihl-Jensen et al., 2015; Chatterjee et al., 2015; Huang et al.,
2015), although there are signs that statin use in patients
with intracerebral hemorrhage may be associated with improved
mortality and functional outcomes (Jung et al., 2015). One
reason for inconsistency or lack of effect is the very limited infor-
mation we have on brain exposure and pharmacodynamics for
statins in general. It is generally considered that lipophilic statins
like simvastatin lactone cross the blood-brain barrier, whereas
atorvastatin, which is relatively less lipophilic, does not (Serajud-
din et al., 1991). However, we performed a pharmacokinetic
study (not shown) for cerivastatin and simvastatin and found
both to have extremely short half-lives in rodents, whether
administered centrally or peripherally.
Patients expected to have high endogenous levels of pre-
nylation in their motor neurons, through higher expression of
PGGT1B, showed earlier ALS onset, perhaps due to their
reduced ability to reinnervate denervated muscle fibers (see
model in Figure 6F). We did not find a difference in basal
outgrowth between the ALS and control hiPS-MNs we analyzed
in vitro. However, this was not unexpected, since hiPS-MNs are
embryonic in phenotype and have not been exposed to the mul-
tiple epigenetic influences that may lead to changes in genef Patients with Early-Onset ALS as Compared to Late-Onset Patients
nches of themevalonate pathway, we calculated the significance of the overall
e between the values in early-onset (<60 years) and late-onset (>60 years) ALS
t of PGGT-1, showed a significant correlation with age of onset as well as a
es.
ALS patients (green) and controls (red). Whereas ALS and control values were
nset patients expressed high levels of PGGT1B that decreased progressively
er the same age range or in dorsal spinal neurons from the same ALS patients
rowth. Levels of PFT and PGGT-1 are high (bold red font) in untreated neurons
gle enzyme is not sufficient to completely remove the brake, whereas inhibiting
old increase in axonal length. Laser-capture microarray profiling suggests that
els of PFT; this may not be sufficient to allow regenerative axonal sprouting. The
tent with their having delayed the onset of physical manifestations through their
expression in adult human neurons. Based on our data, one hy-
pothesis would be that patients taking statins would show a
greater propensity for compensatory axonal sprouting, meaning
that with a given risk from other causes, they would either
develop ALS later or not at all. Although earlier meta-analyses
were not conclusive (Zheng et al., 2013), a recent large study
(722 ALS patients and 2,268 controls) showed evidence for a
protective effect of statins against the onset of ALS (Seelen
et al., 2014). In accordance with our hypothesis, the major
contributor to the improved odds ratio was simvastatin, which
is considered the most brain penetrant of the statins.
Our data show that neurons in multiple contexts maintain
endogenous levels of prenylation that restrict their maximum
growth capacity. In the adult CNS, exuberant sprouting might
lead to circuit dysfunction and behavioral abnormalities. How-
ever, it is less clear why embryonic neurons growing on permis-
sive substrata would need a brake on their growth. One intriguing
possibility is raised by studies of extracellular signaling mole-
cules such as semaphorins, which control not only the direction
but also the timing of axon growth to specific territories during
embryogenesis (Huber et al., 2005). Therefore, activity of theme-
valonate-prenylation pathway may potentially govern the estab-
lishment of neural circuits in a cell-intrinsic manner.
Overall, our data support the idea that the mevalonate-preny-
lation pathway represents a target for therapeutic approaches to
currently incurable diseases and trauma of the CNS. Although
the small molecules currently available to target the pathway
have limitations in terms of bioavailability and rare on-target
toxicity (Cziraky et al., 2013), the exceptional potency of the ef-
fects they engender in model systems suggests that therapeutic
strategies to inhibit prenylation should be pursued for currently
incurable diseases such as ALS.EXPERIMENTAL PROCEDURES
mES-MN and hiPS-MN Differentiation
Mouse ESCs carrying the Hb9::GFP transgene were differentiated into motor
neurons as described previously (Wichterle et al., 2002). Human ES-MNs and
hiPS-MNs from healthy control and ALS patients were differentiated as
described in Lamas et al. (2014) (Amoroso et al., 2013; Boulting et al., 2011;
Maury et al., 2015). Briefly, human ESC colonies were cultured in ESCmedium
with 20 ng/ml basic fibroblast growth factor (bFGF) for 4 days before they were
switched to neural induction medium (DMEM/F12 medium with 1 mM retinoic
acid and 10 ng/ml brain-derived neurotrophic factor [BDNF]). Medium was re-
placed after 4 days and replenished with 1 mM retinoic acid and 200 ng/ml
sonic hedgehog protein (SHH) for 13 days. Embryoid bodies were cultured
for another 10 days in neural differentiation medium (Neurobasal medium sup-
plemented with 1 mM retinoic acid, 200 ng/ml SHH, 2% B-27 supplement
[Invitrogen], 10 ng/ml BDNF, 10 ng/ml ciliary neurotrophic factor (CNTF),
10 ng/ml glial cell line-derived neurotrophic factor (GDNF), and 10 ng/ml
IGF-1) before they were dissociated.
Purified Hb9::GFP human ES-MNs were sorted based on GFP expression
using a BD FACS Aria II sorter (Becton Dickinson) under low-pressure condi-
tions for 30 min. 1,000–2,000 purified GFP-positive cells were plated onto
MAG-CHO cell monolayer in each of the 96 wells.
Neurite Outgrowth Assay on MAG or CSPG
Confluent monolayers of control and MAG-expressing CHO cells were estab-
lished over a 24-hr period in 96-well microplates with transparent bases
(Greiner Bio One). Embryoid bodies were dissociated, and 2,500 mature
ES-MNs were plated onto monolayers in each well in Neurobasal medium(catalog no. 21103-049 without phenol red, without riboflavin) containing
B27 2% glutamine 0.5 mM, glutamate 0.025 mM, b-mercaptoethanol 0.1%,
and CNTF 10 ng/ml. For CSPG inhibition, microplates were coated with
poly-D-ornithine (100 mg/ml) and laminin (3 mg/ml). ES-MNs were seeded,
and CSPG was added to the neuronal cultures at 10 mg/ml. After 18–20 hr,
whole-well images of GFP-positive ES-MNs were captured using a Flash
Cytometer (Trophos) and analyzed for average neurite length per cell using
MetaMorph (Molecular Devices) image analysis software. Detailed procedures
for imaging and analyzing other neuronal cell types are listed in the Supple-
mental Experimental Procedures.
High-Throughput Screen
Compounds were added to the ES-MN culture at final concentration of 10 mM
with 0.5% DMSO.
Neurite outgrowth data were converted to fold change by normalizing them
to mean neurite length of the six negative controls (mock treatment with blank
vehicle) in each plate. Compounds that gave values >1.3-fold those of negative
controls were picked as putative hits, and images of those data points were
visually screened to remove false positives caused by auto-fluorescence.
The primary hits were then tested in a duplicated five-point 2-fold dilution se-
ries. Compounds that showed >30% enhancing effect were purchased from
original vendors and tested in a nine-point 2-fold dilution series in six repli-
cates. Compounds that showed >80% enhancing effect consistently were
identified as the leads.
Chemical Libraries
Using this assay, we first performed a pilot screen of a small library of 2,000
bioactive compounds including US Food and Drug Administration (FDA)-
approved and natural compounds (MicroSource) (Figure 1E). Subsequently,
we screened two other libraries, TIC and BBB, developed by the Stockwell
lab (Columbia University). The TIC library was assembled from natural product
libraries purchased from commercial sources and was designed by selecting
several chemical features according to the following rules: (1) limit the number
of steroids, which are heavily studied and can have pleiotropic effects; (2)
maximize the number of chiral centers and therefore the structural complexity;
and (3) minimize unsaturated rings that are less abundant in natural products.
Compounds in the BBB library were specifically selected to be drug-like and
likely to cross the blood-brain barrier as defined by an in silico filtering protocol
(Brent Stockwell, unpublished data). Compounds with predicted logBB values
(logarithm of the brain-to-blood partitioning ratio) greater than zero (on a log
scale from 3 to +6) were selected first. Of these compounds, those with
molecular weights <250 or containing more than two aromatic rings were dis-
carded to eliminate very simple compounds and highly fluorescent or planar
compounds that might intercalate into DNA.
Optic Nerve Crush and Intravitreal Injection
All animal procedures followed the regulatory guidelines of the Columbia Uni-
versity Institutional Animal Care and Use Committee. The optic nerve crush
and the intravitreal injection in 6- to 8-week-old mice were performed as
described previously (Park et al., 2008). After the nerve crush, 2 ml of saline
or cerivastatin, GGTI-2417, FTI 2153 or combinations of GGTI-2417 and
FTI-2153 at different concentrations was intravitreally injected into the periph-
eral retina. Each compound (2 ml) is diluted 1:10 in the vitreous based on the
fact that the vitreous volume is 20 ml (Saszik et al., 2002). 14 days after injury,
2 ml cholera toxin b subunit coupled to Alexa Fluor 555 (CTB-555) (1 mg/ml, Life
Technologies) was intravitreally injected into the retina. 3 days after CTB injec-
tion, the eye with optic nerve was dissected out, post-fixed in 4% PFA over-
night, and cryoprotected in 30% sucrose in PBS. Eye and optic nerves were
separately frozen on dry ice, and 10-mm cryosections were prepared for
axon regeneration and RGC survival analysis.
Automated Quantification of Axon Regeneration and RGC Survival
To quantify CTB-labeled regenerating axons, three cryosections of2mmop-
tic nerve per animal were washed with PBS and mounted with an aqueous
mounting medium. CTB-labeled regenerating axons were imaged in grayscale
using a constant exposure time. In each section, ImageJ provided amean gray
value of CTB-labeled axons in each 200-mmoptic nerve column from the lesionCell Reports 16, 545–558, July 12, 2016 555
site after removing the value on background (non-tissue area) in the same im-
age. The average of mean gray value of regenerating axons in each 200-mm
optic nerve column was obtained from three sections per animal. Each condi-
tion was tested with three to six animals (n = 3–6). To obtain length of the five
longest axons, the distance of the five longest axon tips from the injury site was
measured with ImageJ in each section. The average of the five longest axons
was obtained from three sections per animal. Each condition was tested with
three to six animals (n = 3–6). To examine RGC survival, the 60th–80th sections
of 150 sagittal cryosections of the whole retina per animal were immuno-
stained with anti-b-III tubulin antibody. Five sections among them were
selected randomly for the analysis. After counting the number of Tuj1+ cells
in all five sections per animal, the average number of b-III tubulin+ cells in
the retina per animal was obtained, and it was pursued repeatedly with three
animals in the same condition (n = 3).
Analysis of Gene Expression Data from Postmortem ALS
The expression data were generated on the Affymetrix HuEx_1_0_st_v2 chip
and normalized using the robust multi-array average (RMA) method. To test
how the expression levels of a gene of interest vary with age (at death/sample
collection) in ALS patients or healthy controls, a linear model was fitted be-
tween the log-intensity values and the age at sample collection. Disease dura-
tion did not vary significantly among the ALS patients, and the age at onset and
age at death were highly correlated (data not shown). The R2 (unadjusted) and
p values of the coefficient for age in this model are reported in Figure 6A (col-
umn 3). To test whether the genes of interest are expressed differentially be-
tween late-onset and early-onset ALS patients, a linear model was fit between
the log-intensity values and the ALS categorization (early, late, or control). The
p values of the coefficients in this fit are reported in Figure 6A (column 4). Since
the above analyses were done on genes comprising the mevalonate pathway
(<20 genes) only, we report only the unadjusted p values. All analyses were
done in the statistical language R.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.06.013.
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